Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Secukinumab
Drug: Ustekinumab

First Posted Date: 2016-07-11

Last Posted Date: 2019-07-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1114

Registration Number: NCT02826603

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

Not Applicable

Completed

Conditions: Chronic Heart Failure (CHF)

Interventions: Procedure: Standard care

First Posted Date: 2016-06-21

Last Posted Date: 2021-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1415

Registration Number: NCT02807857

Locations: 🇪🇸
Novartis Investigative Site, Panxon, Spain

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Pancreatic Carcinoma
Triple Negative Breast Cancer
Melanoma
Endometrial Carcinoma

Interventions: Drug: MCS110
Drug: PDR001

First Posted Date: 2016-06-21

Last Posted Date: 2021-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 141

Registration Number: NCT02807844

Locations: 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇨🇭
Novartis Investigative Site, Zuerich, Switzerland

and more 2 locations

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Phase 4

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Secukinumab 300 mg
Drug: Secukinumab 150 mg
Other: Placebo

First Posted Date: 2016-06-14

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 258

Registration Number: NCT02798211

Locations: 🇵🇷
Novartis Investigative Site, Santurce, Puerto Rico

Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Phase 3

Withdrawn

Conditions: Psoriasis

Interventions: Drug: "Secukinumab" "Cosentyx TM"

First Posted Date: 2016-06-10

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02795416

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1

Completed

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Spartalizumab
Drug: Capmatinib

First Posted Date: 2016-06-10

Last Posted Date: 2023-07-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT02795429

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Teriflunomide capsule
Drug: Ofatumumab subcutaneous injection
Drug: Teriflunomide-matching placebo capsules
Drug: Matching placebo of ofatumumab subcutaneous injections

First Posted Date: 2016-06-07

Last Posted Date: 2021-10-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 930

Registration Number: NCT02792218

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Phase 3

Completed

Conditions: Relapsing Multiple Scelrosis

Interventions: Drug: Ofatumumab subcutaneous injection
Drug: Teriflunomide capsule
Drug: Teriflunomide-matching placebo capsules
Drug: Matching placebo of ofatumumab subcutaneous injections

First Posted Date: 2016-06-07

Last Posted Date: 2021-11-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 955

Registration Number: NCT02792231

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Registry of Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Secikinumab

First Posted Date: 2016-05-30

Last Posted Date: 2024-11-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2384

Registration Number: NCT02786186

Locations: 🇵🇦
Novartis Investigative Site, Panama, Panama

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Drug: CDZ173
Drug: Placebo

First Posted Date: 2016-05-18

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT02775916

Locations: 🇭🇺
Novartis Investigative Site, Debrecen, Hungary

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy